Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

patient experience

- PMLiVE

Sarepta to submit application for Duchenne muscular dystrophy gene therapy

The condition occurs in approximately one in every 3,500-5,000 newborn males worldwide

COS and Genesis Research

Genesis Research and Clinical Outcomes Solutions announce innovative partnership

International Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) organization Genesis Research is delighted to announce an exciting new partnership with Clinical Outcomes Assessment (COA) specialist Clinical Outcomes...

Genesis Research Group

Genesis Research & MAT logo

Genesis Research Acquires Market Access Transformation

Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services, has entered into a definitive agreement to acquire Market Access Transformation (“MAT”),...

Genesis Research Group

Genesis Research – an introduction

Genesis Research Group

Ensuring fit-for-purpose real-world data to generate real-world evidence with Susan Oliveria

Genesis Research Group

- PMLiVE

6 trends shaping the future of personalized medicine

Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators.

Avalere Health

6 professional headshots of the 4 women and 2 men on the leadership team at Avalere

Data-driven policy and market access firm Avalere joins Fishawack Health

Fishawack Health bolsters its commercialization service offering with its largest addition to date, welcoming US-based policy, market access, and transformation leader Avalere.

Avalere Health

- PMLiVE

How whole genome sequencing is revolutionising the rare disease patient experience

In this white paper, we discuss how whole genome sequencing (WGS) projects and the data sets they produce are paving the way for developments in research, diagnosis, and early interventions...

IGNIFI

- PMLiVE

bluebird bio maintains its focus on gene therapy opportunities during structural changes

The company plans to reduce its workforce amid efforts to reduce its operating costs

Democratizing Brain Health with Digital Assessments

Dr. Pam Ventola, Senior Science Director at Cogstate, shares how the company is working to optimize brain health assessments in rare disease and pediatric clinical trials, and how this can...

Impetus Digital

- PMLiVE

Novartis and Voyager Therapeutics agree on gene therapy deal worth 1.7bn

The licence option agreement is for next-generation gene therapy vectors for neurological diseases

- PMLiVE

bluebird bio shares therapy updates for 2022

The company provided information for its first two gene therapies and its lovo-cel BLA submission for sickle cell disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links